<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03477162</url>
  </required_header>
  <id_info>
    <org_study_id>D17188</org_study_id>
    <nct_id>NCT03477162</nct_id>
  </id_info>
  <brief_title>Metformin Pharmacology in Human Cancers: A Proof of Principle Study</brief_title>
  <official_title>Metformin Pharmacology in Human Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a presurgical (proof of principle, window of opportunity) study in patients with
      surgically resectable thoracic tumors to determine steady-state tissue and plasma
      concentrations of metformin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To understand the variability in clinical results testing metformin as an anti-cancer agent,
      it is important to determine the concentrations of metformin that are achievable in tissue.
      Clinical effects of metformin develop gradually over several days of treatment. Steady-state
      plasma metformin concentrations are correlated with anti-hyperglycemic response. Thus,
      achieving steady-state concentrations in this study will allow accurate determination of the
      most representative concentrations of metformin in normal and cancerous tissues, as well as
      determine AMP-activated protein kinase (AMPK) signaling differences in these tissues. As tha
      Primary Objective is to determine the concentration of metformin in tumors, patients will be
      treated with metformin extended release (ER) (Glucophage® XR), starting at 750 milligrams
      (mg) oral (PO) once daily (QD) for 4 days, then escalating to 750 mg PO twice daily (BID) for
      3-6 days prior to surgery. FDA prescribing information indicates that metformin reaches
      steady-state plasma concentrations within 24-48 hours after the start of dosing in humans;
      thus, the 7-to-10-day time frame of this study will allow sufficient time for metformin to
      reach steady-state plasma concentrations, in addition to time allotted for potential
      accumulation in tissues. Metformin concentrations will be measured using a validated liquid
      chromatography-mass spectrometry (LC-MS/MS) assay.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor concentration of Metformin</measure>
    <time_frame>Within 7 days from surgery</time_frame>
    <description>To determine the intra-tumor concentrations of metformin, with a standard deviation ≤25% of the mean, in patients with solid tumors of thoracic origin administered metformin extended release.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of Metformin in adipose tissue</measure>
    <time_frame>Within 7 days from surgery</time_frame>
    <description>To determine the concentration of metformin in adipose tissue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Metformin in tumor-adjacent normal tissue</measure>
    <time_frame>Within 7 days from surgery</time_frame>
    <description>To determine the concentration of metformin in tumor-adjacent normal tissue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Metformin in plasma.</measure>
    <time_frame>Within 7 days from surgery</time_frame>
    <description>To determine the concentration of metformin in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Metformin in whole blood.</measure>
    <time_frame>Within 7 days from surgery</time_frame>
    <description>To determine the concentration of metformin in whole blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AMPK activity alterations.</measure>
    <time_frame>Within 7 days from surgery.</time_frame>
    <description>To determine whether metformin alters AMPK activity in tumor cells.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Thoracic Neoplasm</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients enrolled will be treated with metformin (administered orally; 750 mg QD for 4 days, then 750 mg BID for 3-6 days; or clinically indicated metformin) for a total of 7-10 days prior to surgery, up until the night before surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin will be given to patients prior to surgery.</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Invasive malignant solid tumor of thoracic origin (e.g., lung, esophageal, thymus,
             mesothelioma, chest wall, mediastinum, trachea, pleura) with the intent to treat or
             biopsy by surgery as standard of care. Tumor must be ≥2 centimeters (cm).

          -  Patients with multicentric disease are eligible. Samples from all available tumors are
             requested for research purposes.

          -  Patients with Type 2 diabetes mellitus being treated with metformin (any dose) for a
             clinical indication at the time of study enrollment are eligible, and will continue
             metformin treatment as clinically indicated during the presurgical study period. Their
             dose of metformin will NOT be changed.

          -  Patients not on metformin at the time of study entry must be willing to take metformin
             extended release (Glucophage® XR, 750 mg QD for 4 days, then 750 mg BID for 3-6 days)
             for a total of 7-10 days prior to surgery.

          -  Patients do not require a diagnosis of diabetes to be enrolled in the study.

          -  All patients must be willing to keep a drug diary indicating the dates and times of
             metformin administration.

        Patients must meet the following clinical laboratory criteria:

          -  Absolute neutrophil count (ANC) greater than or equal to 1,500/mm3 and platelet count
             greater than or equal to 75,000/mm3.

          -  Total bilirubin less than or equal to 1.5x the upper limit of the normal range (ULN).

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than or equal
             to 3x ULN.

          -  Estimated glomerular filtration rate (eGFR) &gt; 60 mL/min/1.73m2 or estimated creatinine
             clearance (eCrCL) &gt; 60 mL/min

          -  Ability to give informed consent.

          -  Patients must be willing to provide 20 milliliters (mL) of blood for research use.

          -  Patient must be willing to provide consent for use of archived tissue for research.

        Exclusion Criteria:

          -  History of diabetes that is currently being treated without metformin.

          -  Patients who, at the time of study entry, are not taking metformin for a clinical
             indication, and who will need a radiographic analysis with an iodinated contrast agent
             during the metformin study treatment period.

          -  This criterion does not apply to patients taking clinically indicated metformin at the
             time of study entry.

          -  History of liver disease as defined with liver function tests (LFTs) above those in
             the inclusion

          -  Known hypersensitivity to metformin.

          -  History of reactive hypoglycemia.

          -  Active or history of lactic acidosis, metabolic acidosis, or diabetic ketoacidosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Phillips, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kayla Fay</last_name>
    <phone>603-650-8537</phone>
    <email>Kayla.A.Fay@hitchcock.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Research Nurse</last_name>
    <phone>800-639-6918</phone>
    <email>cancer.research.nurse@dartmouth.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kayla Fay</last_name>
      <phone>603-650-8537</phone>
      <email>Kayla.A.Fay@hitchcock.org</email>
    </contact>
    <contact_backup>
      <last_name>Research Nurse</last_name>
      <phone>800-639-6918</phone>
      <email>cancer.research.nurse@dartmouth.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009 Jan;32(1):193-203. doi: 10.2337/dc08-9025. Epub 2008 Oct 22.</citation>
    <PMID>18945920</PMID>
  </reference>
  <reference>
    <citation>Witters LA. The blooming of the French lilac. J Clin Invest. 2001 Oct;108(8):1105-7. Review.</citation>
    <PMID>11602616</PMID>
  </reference>
  <reference>
    <citation>Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012 Mar;122(6):253-70. doi: 10.1042/CS20110386. Review.</citation>
    <PMID>22117616</PMID>
  </reference>
  <reference>
    <citation>Rena G, Pearson ER, Sakamoto K. Molecular mechanism of action of metformin: old or new insights? Diabetologia. 2013 Sep;56(9):1898-906. doi: 10.1007/s00125-013-2991-0. Epub 2013 Jul 9. Review.</citation>
    <PMID>23835523</PMID>
  </reference>
  <reference>
    <citation>Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001 Oct;108(8):1167-74.</citation>
    <PMID>11602624</PMID>
  </reference>
  <reference>
    <citation>Gunton JE, Delhanty PJ, Takahashi S, Baxter RC. Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2. J Clin Endocrinol Metab. 2003 Mar;88(3):1323-32. Erratum in: J Clin Endocrinol Metab. 2004 Jan;89(1):434.</citation>
    <PMID>12629126</PMID>
  </reference>
  <reference>
    <citation>El-Mir MY, Nogueira V, Fontaine E, Avéret N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000 Jan 7;275(1):223-8.</citation>
    <PMID>10617608</PMID>
  </reference>
  <reference>
    <citation>DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995 Aug 31;333(9):541-9.</citation>
    <PMID>7623902</PMID>
  </reference>
  <reference>
    <citation>Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):854-65. Erratum in: Lancet 1998 Nov 7;352(9139):1558.</citation>
    <PMID>9742977</PMID>
  </reference>
  <reference>
    <citation>Hurst RT, Lee RW. Increased incidence of coronary atherosclerosis in type 2 diabetes mellitus: mechanisms and management. Ann Intern Med. 2003 Nov 18;139(10):824-34. Review.</citation>
    <PMID>14623620</PMID>
  </reference>
  <reference>
    <citation>Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, Ray JE, Timmins P, Williams KM. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011 Feb;50(2):81-98. doi: 10.2165/11534750-000000000-00000. Review.</citation>
    <PMID>21241070</PMID>
  </reference>
  <reference>
    <citation>Christensen MM, Brasch-Andersen C, Green H, Nielsen F, Damkier P, Beck-Nielsen H, Brosen K. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics. 2011 Dec;21(12):837-50. doi: 10.1097/FPC.0b013e32834c0010. Erratum in: Pharmacogenet Genomics. 2015 Jan;25(1):48-50.</citation>
    <PMID>21989078</PMID>
  </reference>
  <reference>
    <citation>Timmins P, Donahue S, Meeker J, Marathe P. Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin Pharmacokinet. 2005;44(7):721-9.</citation>
    <PMID>15966755</PMID>
  </reference>
  <reference>
    <citation>Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, Burchard EG, Brett CM, Giacomini KM. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 2007 May;117(5):1422-31.</citation>
    <PMID>17476361</PMID>
  </reference>
  <reference>
    <citation>Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol. 1981 Aug;12(2):235-46.</citation>
    <PMID>7306436</PMID>
  </reference>
  <reference>
    <citation>Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. Diabetes Care. 2010 Jul;33(7):1674-85. doi: 10.2337/dc10-0666.</citation>
    <PMID>20587728</PMID>
  </reference>
  <reference>
    <citation>Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care. 2010 Jun;33(6):1304-8. doi: 10.2337/dc09-1791. Epub 2010 Mar 18.</citation>
    <PMID>20299480</PMID>
  </reference>
  <reference>
    <citation>Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2010 Nov;3(11):1451-61. doi: 10.1158/1940-6207.CAPR-10-0157. Epub 2010 Oct 12. Review.</citation>
    <PMID>20947488</PMID>
  </reference>
  <reference>
    <citation>Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005 Jun 4;330(7503):1304-5. Epub 2005 Apr 22.</citation>
    <PMID>15849206</PMID>
  </reference>
  <reference>
    <citation>Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009 Jul 10;27(20):3297-302. doi: 10.1200/JCO.2009.19.6410. Epub 2009 Jun 1.</citation>
    <PMID>19487376</PMID>
  </reference>
  <reference>
    <citation>Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology. 2009 Aug;137(2):482-8. doi: 10.1053/j.gastro.2009.04.013. Epub 2009 Apr 16.</citation>
    <PMID>19375425</PMID>
  </reference>
  <reference>
    <citation>Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009 Sep;32(9):1620-5. doi: 10.2337/dc08-2175. Epub 2009 Jun 29.</citation>
    <PMID>19564453</PMID>
  </reference>
  <reference>
    <citation>Wright JL, Stanford JL. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control. 2009 Nov;20(9):1617-22. doi: 10.1007/s10552-009-9407-y. Epub 2009 Aug 4.</citation>
    <PMID>19653109</PMID>
  </reference>
  <reference>
    <citation>Xu H, Aldrich MC, Chen Q, Liu H, Peterson NB, Dai Q, Levy M, Shah A, Han X, Ruan X, Jiang M, Li Y, Julien JS, Warner J, Friedman C, Roden DM, Denny JC. Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality. J Am Med Inform Assoc. 2015 Jan;22(1):179-91. doi: 10.1136/amiajnl-2014-002649. Epub 2014 Jul 22.</citation>
    <PMID>25053577</PMID>
  </reference>
  <reference>
    <citation>Chae YK, Arya A, Malecek MK, Shin DS, Carneiro B, Chandra S, Kaplan J, Kalyan A, Altman JK, Platanias L, Giles F. Repurposing metformin for cancer treatment: current clinical studies. Oncotarget. 2016 Jun 28;7(26):40767-40780. doi: 10.18632/oncotarget.8194. Review.</citation>
    <PMID>27004404</PMID>
  </reference>
  <reference>
    <citation>Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007 Nov 15;67(22):10804-12.</citation>
    <PMID>18006825</PMID>
  </reference>
  <reference>
    <citation>Mohammed A, Janakiram NB, Brewer M, Ritchie RL, Marya A, Lightfoot S, Steele VE, Rao CV. Antidiabetic Drug Metformin Prevents Progression of Pancreatic Cancer by Targeting in Part Cancer Stem Cells and mTOR Signaling. Transl Oncol. 2013 Dec 1;6(6):649-59. eCollection 2013 Dec 1.</citation>
    <PMID>24466367</PMID>
  </reference>
  <reference>
    <citation>Zakikhani M, Blouin MJ, Piura E, Pollak MN. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat. 2010 Aug;123(1):271-9. doi: 10.1007/s10549-010-0763-9. Epub 2010 Feb 5.</citation>
    <PMID>20135346</PMID>
  </reference>
  <reference>
    <citation>Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO, de Vries EG. Metformin: taking away the candy for cancer? Eur J Cancer. 2010 Sep;46(13):2369-80. doi: 10.1016/j.ejca.2010.06.012. Epub 2010 Jul 23. Review.</citation>
    <PMID>20656475</PMID>
  </reference>
  <reference>
    <citation>Poloz Y, Stambolic V. Obesity and cancer, a case for insulin signaling. Cell Death Dis. 2015 Dec 31;6:e2037. doi: 10.1038/cddis.2015.381. Review.</citation>
    <PMID>26720346</PMID>
  </reference>
  <reference>
    <citation>Camacho L, Dasgupta A, Jiralerspong S. Metformin in breast cancer - an evolving mystery. Breast Cancer Res. 2015 Jun 26;17:88. doi: 10.1186/s13058-015-0598-8.</citation>
    <PMID>26111812</PMID>
  </reference>
  <reference>
    <citation>Dowling RJ, Lam S, Bassi C, Mouaaz S, Aman A, Kiyota T, Al-Awar R, Goodwin PJ, Stambolic V. Metformin Pharmacokinetics in Mouse Tumors: Implications for Human Therapy. Cell Metab. 2016 Apr 12;23(4):567-8. doi: 10.1016/j.cmet.2016.03.006.</citation>
    <PMID>27076069</PMID>
  </reference>
  <reference>
    <citation>Kajbaf F, De Broe ME, Lalau JD. Therapeutic Concentrations of Metformin: A Systematic Review. Clin Pharmacokinet. 2016 Apr;55(4):439-59. doi: 10.1007/s40262-015-0323-x. Review.</citation>
    <PMID>26330026</PMID>
  </reference>
  <reference>
    <citation>Glucophage XR product insert. https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=web&amp;cd=1&amp;ved=0ahUKEwjcrMLO8cPXAhWGZiYKHVe1DoMQFggrMAA&amp;url=https%3A%2F%2Fpackageinserts.bms.com%2Fpi%2Fpi_glucophage.pdf&amp;usg=AOvVaw2zAbyMgwlF7wxaXv60vtv3.</citation>
  </reference>
  <reference>
    <citation>Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011 Jun;34(6):1431-7. doi: 10.2337/dc10-2361. Review.</citation>
    <PMID>21617112</PMID>
  </reference>
  <reference>
    <citation>Wadamori N, Shinohara R, Ishihara Y. Photoacoustic depth profiling of a skin model for non-invasive glucose measurement. Conf Proc IEEE Eng Med Biol Soc. 2008;2008:5644-7. doi: 10.1109/IEMBS.2008.4650494.</citation>
    <PMID>19163997</PMID>
  </reference>
  <reference>
    <citation>Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2012 Apr;35(4):731-7. doi: 10.2337/dc11-1299.</citation>
    <PMID>22442396</PMID>
  </reference>
  <reference>
    <citation>Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB, Brancati FL. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007 Sep 18;147(6):386-99. Epub 2007 Jul 16. Review. Erratum in: Ann Intern Med. 2007 Dec 18;147(12):887.</citation>
    <PMID>17638715</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2018</study_first_submitted>
  <study_first_submitted_qc>March 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2018</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dartmouth-Hitchcock Medical Center</investigator_affiliation>
    <investigator_full_name>Joseph D. Phillips, MD.</investigator_full_name>
    <investigator_title>Staff Physician, Thoracic Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thoracic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

